Page 44 - Towards personalized therapy for metastatic prostate cancer: technical validation of [18F]fluoromethylcholine

Chapter 2
22. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, et al. Sentinel lymph node dissection for prostate cancer: experience with more than 1000 patients. J Urol. 2007;177:916–920
23. Jager GJ, Barentsz JO, Oosterhof GO, Witjes JA and Ruijs SJ. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol. 1996;167:1503–1507
24. Beer AJ, Eiber M, Souvatzoglou M, Holzapfel K, Ganter C, et al. Restricted water diffusibility as measured by diffusion-weighted MR imaging and choline uptake in (11)C-choline PET/CT are correlated in pelvic lymph nodes in patients with prostate cancer. Mol Imaging Biol. 2011;13(2):352–361
25. DeGrado TR, Coleman RE, Wang S, Baldwin SW, Orr MD, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110–117
26. Iwata R, Pascali C, Bogni A, Furumoto S, Terasaki K, et al. [18F]fluoromethyl triflate, a novel and reactive [18F] fluoromethylating agent: preparation and application to the on-column preparation of [18F]fluorocholine. Appl Radiat Isot. 2002;57:347–352
27. Windhorst AD, ter Linden T, de Nooij A, Keus JF, Buijs FL, et al. A complete, multipurpose, low cost, fully automated and GMP compliant radiosynthesis system. J Labelled Cpd Radiopharm. 2001;44:1052–1054
28. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200
29. Cheebsumon P, van Velden FH, Yaqub M, Frings V, de Langen AJ, et al. Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment. J Nucl Med. 2011;52:1550–1558
30. Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med. 2010;51:1870–1877
31. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387–395
32. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–1400
33. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, et al. The detection rate of [11C]Choline- PET/CT depends on the serum PSAvalue in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18–23
34. Fuccio C, Castellucci P, Schiavina R, Santi I, Allegri V, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med. 2010;24:485–492
35. Breeuwsma AJ, Pruim J, van den Bergh AC, Leliveld AM, Nijman RJ, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using 11C-choline positron emission tomography. Int J Radiat Oncol Biol Phys. 2010;77:60–64
36. Rinnab L, Mottaghy FM, Blumstein NM, Reske SN, Hautmann RE, et al. Evaluation of [11C]-choline positron- emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 2007;100:786–793
37. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, et al. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:45–53
38. Hartemink KJ, Muller S, Smulders YM, Petrousjka van den Tol M and Comans EF. Fluorodeoxyglucose F18(FDG)-probe guided biopsy. Ned Tijdschr Geneeskd. 2010;154:A1884
42